More work needs to be done to support Massachusetts veterans, state secretary says
Massachusetts Secretary of Veterans' Services Jon Santiago said on this Memorial Day, more needs to be done for veterans in the state, especially with ensuring there's enough staff to support and care for them.
Memorial Day is much more than a day off and the start of the summer season. For 155 years, it has been a day reserved for honoring the sacrifices made by military personnel who die while serving our country.
Santiago, who is a major in the U.S. Army Reserve, was asked if he thinks the public has forgotten the true meaning of Memorial Day.
"I think the values that Memorial Day represents [are] still very much alive in people all across the Commonwealth, all across this country. Now whether there is a diminished patriotism when it comes to certain events, perhaps, but for Memorial Day, what this is about, to me and to so many other folks that I interact with on a daily basis, it's about reflection and gratitude and really acknowledging the sacrifice borne by generations of Americans for 250-plus years that have allowed us to be who we are, to share these values and to have the freedoms that govern how we live in society today. For me, it's a moment of gratitude. It's really a sacred American day," said Santiago.
Fixing veterans homes after COVID deaths
That said, Santiago turned to the challenges facing many of the state's 200,000-plus veterans. "Whether it's PTSD, substance use, a whole host of issues, but there are also generations of veterans who have been here for decades who are still looking for care. Think about our Vietnam veterans, our Korean War veterans who are getting up there in age that need that support," he said.
During the height of the COVID pandemic, dozens of veterans died in the state's two Soldiers Homes due to mismanagement, and Santiago says fixing those facilities in Chelsea and Holyoke has been a top priority. The institutions were "using paper medical charts, paper scheduling, not licensed to be nursing homes, ran by people not licensed to run nursing homes with dilapidated infrastructure. Over the course of two years, we've completely turned that around, and I can show you that with outcomes, [people] telling us that care is better, quality is better, and folks are excited about being there."
Concerns about VA staffing
It's been a couple of months since we learned that the Federal Department of Veterans Affairs planned to cut 17% of the workforce at the VA, 83,000 jobs nationally. How is what has happened since affecting services here in our state?
"This is increasingly concerning," says Sec. Santiago. "We're talking about a 15% decrease in staff supporting veterans, whether that's at the VA or some of the other centers that the VA utilizes. We need that support of staff to do the work that we need to do, and so we're already seeing cuts to services across not just the Commonwealth, but across the country.... It raises significant concerns on whether veterans will be able to access their care."
Santiago also discussed the potential impact of Medicaid cuts included in the House tax bill passed last week, and steps he's been taking to improve services for female veterans. You can watch the entire interview here, and please join us every Sunday morning at 8:30am for more interviews with newsmakers in public policy on the weekend edition of "Keller At Large."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
26 minutes ago
- Medscape
Should Kids Get the HPV Vaccine Earlier?
Recommending the human papillomavirus (HPV) vaccination to parents of 9- to 10-year-old children allowed clinicians to discuss cancer prevention and avoid the sticky subject of sexual activity that often comes up with older age groups, new research showed. The study, published in Pediatrics , also found that parents were generally open to having their 9- to 10-year-old children vaccinated for HPV. 'At ages 9-10, sexual activity was less salient, and HPV was the only vaccine to discuss,' said Caroline Tietbohl, PhD, an assistant professor in the Department of Family Medicine at the University of Colorado in Aurora, Colorado, and lead author of the study. 'This made discussions shorter and easier and also paid forward to the 11-year-old visit, where there was now one less vaccine to discuss.' HPV is the most common sexually transmitted infection in the US, with approximately 42 million people currently infected. The US CDC currently recommends the HPV series vaccine as part of routine vaccination beginning at age 11 years, but states that vaccination can start at age 9 years. The vaccine is highly effective for preventing several types of cancer, including cervical and oropharyngeal cancers. Two doses are recommended for most people who start the series before age 15 years, and three doses are recommended for those who start the series after age 15 years, as well as immunocompromised individuals. Yet only 40% of children between 9 years and 17 years of age have received at least one dose. Tietbohl said her team was motivated to conduct the research by persistently low completion rates of the HPV series despite strong evidence that the vaccine is safe and highly effective at preventing cancer. 'We anticipated that bringing up the HPV vaccine at this age could make the discussion easier by decoupling it from sexual activity and focusing on its purpose — cancer prevention — and this seems to have been true for many parents in our study,' Tietbohl said. She and her colleagues surveyed and interviewed pediatricians and staff between 2021 to 2022 at 17 clinics in Colorado and 16 in California. The practices were randomly assigned to either recommend the HPV vaccine to parents of the younger children or to continue at the current standard at ages of 11-12 years. Surveys assessed how the shift was implemented, while interviews provided more detail about any challenges or benefits observed. Prior to the intervention, none of the clinics had recommended the vaccine to younger patients, instead following the current standard recommendation. One month after the intervention, over 90% of clinicians in Colorado and 77% of those in California reported routinely recommending the vaccine to children at ages 9 years or 10 years. Most clinicians and staff in the intervention group reported that parents were largely receptive to the earlier recommendation, sometimes to the clinician's surprise. Many said they had expected parents to push back, assuming that discussions of the HPV vaccine would raise concerns about sexual activity or be met with hesitation. Instead, they found that conversations were easier at ages 9 years and 10 years because sexual activity was less of a consideration for parents at that age. Angela Myers, MD The findings build on evidence that parents may be more receptive when the discussion starts earlier, said Angela Myers, MD, professor of pediatrics and pediatric infectious diseases at the University of Missouri-Kansas City, who was not involved in the study. 'The earlier we get kids vaccinated against HPV, the better their immune response,' Myers said. 'Sexual activity becomes kind of a nonthought at age 9. That's as it should be because this is a cancer prevention vaccine.' Despite the positive response, some clinicians noted challenges, including electronic health record reminders that still reflected the older age recommendation, as well as occasional parental surprise at being offered the vaccine at a younger age. 'The main hitch was that some parents were not expecting to discuss the HPV vaccine until age 11 and had already promised their kids that the 9- or 10-year-old visit would not include shots,' Tietbohl said. The next phase of the research will focus on analyzing whether earlier vaccination improves rates of series completion by age 13 years, Tietbohl said. Myers said recommending the vaccine earlier could help improve vaccination rates by giving families more time to complete the series before adolescence. 'Every new study that gets published adds a little bit more to the story,' Myers said. 'Collectively, all of the data can help in saying, 'Perhaps we should take another look at this and perhaps we should change the language slightly.' Tietbohl and Myers did not report any relevant conflicts of interest. The study was supported by the National Cancer Institute of the National Institutes of Health.
Medscape
31 minutes ago
- Medscape
Mailed Kits Beat Office Visits for Cervical Cancer Screening
Mailed self-collection kits and a telephone reminder helped increase cervical cancer screening (CCS) rates more than twice as much as telephone reminders for an office visit, according to new data from a randomized clinical trial in a safety-net population. The home kits paired with additional patient contact increased numbers even further. In a trial that included 2474 people overdue for CCS (94% of them from minority populations), participants randomized to a telephone reminder with a mailed self-collection kit had 41.1% participation compared to those with a phone reminder to come in for an office visit (17.4%). CCS rates were modestly higher (46.6%) when people received contact in addition to the telephone reminder and mailed self-collection kit for testing human papillomavirus (HPV). Self-collection with additional patient contact was designed to be different from self-collection with a telephone reminder in terms of the dose of patient interactions rather than content, minimizing potential contamination across the self-collection with telephone reminder and self-collection with additional patient contact groups. The study, led by Jane R. Montealegre, PhD, with the Department of Behavioral Science, The University of Texas MD Anderson Cancer Center in Houston, was conducted from February 20, 2020, to August 31, 2023, and published in JAMA Internal Medicine . Cervical Cancer Could be Eliminated in the US in 10-20 Years Estimates show that cervical cancer in the US could see national-level elimination in the next one to two decades if CCS rates hit 90%. However up-to-date screening has declined in recent years and was 75.2% in 2021, with rates notably lower among underserved populations, including women and people with a cervix who are uninsured or publicly insured, live in rural areas, and are from minority populations. The study researchers noted that the results in this trial, the PRESTIS trial, are consistent with the relative participation rates of previous trials. In a recent meta-analysis of 28 trials, Stefanie Costa and colleagues reported a 2.5-fold higher participation in screening with mailed self-collection vs usual care. 'Notably distinct from previous trials are the large screening proportions attained in the [self-collection (SC) group] (41.1%) and SC with patient navigation (46.6%) groups, as compared to the global estimate of 24% reported in the meta-analysis,' the authors wrote. In an accompanying editorial, Eve Rittenberg, MD, MA, with the Division of Women's Health, Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues wrote that home self-collection 'has the potential to meaningfully reduce cervical cancer burden, especially among underserved populations.' They pointed out that self-collection has previously been studied in a clinical setting, where women can collect a sample privately without undergoing an invasive Pap smear and that 'self-collected HPV samples have similar specificity and sensitivity to clinician-collected samples.' But it hasn't been known whether the tests need to be performed in a clinic. Home Screening May Further Eliminate Barriers Montealegre's team shows that 'home self-collection demonstrates that people can adequately obtain usable samples in the privacy of their homes, as only 6% of samples were deemed inadequate for evaluation,' the editorialists wrote. Home-based screening, they explained, may further eliminate screening barriers for underserved populations with lower costs and fewer logistical hurdles. Additionally, screening via pelvic exam can be uncomfortable and may be culturally unacceptable for some. Pelvic exam-based screening may be particularly distressing to those who have experienced sexual trauma, they wrote. They pointed out that options for CCS are growing with the approval last month by the FDA of a home HPV self-collection kit, which will be available for clinical use within months. Self-collection of HPV samples is included in the World Health Organization's global strategy to eliminate cervical cancer by 2030, and the draft US Preventive Services Task Force CCS guidance now includes self-collection as an option. Future research should help determine whether more home self-collected HPV screening leads to higher rates of treating precancerous lesions and eventually lower cervical cancer rates, the editorialists wrote. They also noted that efforts to increase CCS rates should be accompanied by efforts to increase HPV vaccination rates. The research was funded through grants from the National Institute on Minority Health and Health Disparities and the National Cancer Institute through an MD Anderson Cancer Center Support Grant, the Dan L Duncan Comprehensive Cancer Center Support Grant, and the Hollings Cancer Center Support Grant. The authors reported having no relevant financial relationships. An editorialist, Cary Gross, MD, reported receiving grants from Johnson & Johnson and the National Comprehensive Cancer Network (with funding provided by AstraZeneca) outside the submitted work. No other disclosures were reported.
Medscape
an hour ago
- Medscape
Study Shows Safety of Pharma-Grade CBD for Myocarditis
An oral formulation of pharmaceutically manufactured cannabidiol (CBD) that targets inflammatory pathways in myocarditis and pericarditis has been shown to be as safe as placebo in not elevating cardiovascular risks, results of a prospective trial have shown. The placebo-controlled trial enrolled 89 people with a history of cardiovascular disease (CVD) and/or at least one major risk factor for the condition who had been hospitalized for noncritical COVID-19. Leslie Cooper Jr, MD 'There are 45 or so who received pharmacologically produced CBD who had no increase in overall or cardiovascular adverse events, and in particular there was no prolongation of the QT interval,' Leslie Cooper Jr, MD, chair of cardiovascular medicine at Mayo Clinic Florida in Jacksonville, Florida, told Medscape Medical News . Cooper presented a poster on the study at Heart Failure Association of the European Society of Cardiology (HFA-ESC) 2025. The findings confirmed the safety of CBD doses up to 7.5 mg/kg twice daily used in the ARCHER trial in myocarditis and the MAVERIC trial in pericarditis, Cooper said. Study Shows Safety Signal The researchers designed the study during the COVID-19 pandemic to evaluate if people hospitalized for noncritical COVID-19 with a history of or a risk factor for CVD were also at an increased risk for cardiac inflammation, Cooper said. The study was stopped early because the pandemic ended. 'The findings were underpowered for efficacy, but they did support a safety signal,' he said. The study found no significant differences in adverse events between the CBD and no-CBD groups. For example, the rate of gastrointestinal disorders was 22.2% in the CBD group and 20.5% in the placebo group. Nervous system disorders were observed in 17.8% of CBD patients vs 18.2% of placebo patients. Eleven percent of CBD patients had respiratory, thoracic, and mediastinal disorders compared with 9% of placebo patients. The rates of cardiac adverse events were also similar between the two groups. No patients in the CBD group vs three (6.8%) of those in the placebo group had tachycardia. One case of atrial fibrillation, cardiac failure, left ventricular hypertrophy, and pericardial effusion was observed in the CBD group vs none in the placebo group. One patient in the placebo group vs none in the CBD group had atrial flutter. Most cases of myocarditis are mild and resolve spontaneously without long-term consequences, Cooper said. However, about 25% of cases have significant cardiovascular sequelae, including arrhythmias and heart failure. 'We know, based on clinical grounds, how to identify those complex patients who are probably going to have a rocky long-term course,' he said. New Treatments Needed While one drug, rilonacept (Arcalyst), has been approved for the treatment of recurrent pericarditis, no approved drugs for myocarditis exist. New treatments are also needed for cardiomyopathy. Bettina Heidecker, MD, head of Heart Failure and Cardiomyopathy at the German Charité Heart Center in Berlin, Germany, told Medscape Medical News , said current therapies such as corticosteroids and other immunosuppressants carry long-term risks such as osteoporosis, metabolic disorders, infections, and organ toxicity, 'A pharmaceutically standardized CBD formulation could offer a targeted anti-inflammatory approach with a more favorable side effect profile,' Heidecker told Medscape Medical News . 'This would be particularly beneficial for younger or lower-risk patients, or those in whom prolonged immunosuppression is problematic.' Heidecker said the new data provide a rationale for continued investigation of CBD in myocarditis and pericarditis. 'It will be exciting to investigate how individual patients respond to CBD, particularly early in the treatment course,' she said. Heidecker and her team in Berlin have been studying the utility of noninvasive magnetocardiography to detect myocardial inflammation and monitor response to anti-inflammatory therapy with the hope that the approach 'may help identify early responders and guide personalized treatment strategies with CBD.' The trial was funded by Cardiol Therapeutics. Cooper is a consultant to Cardiol Therapeutics. Heidecker holds patents for RNA-based diagnostics in myocarditis and holds pending patents on magnetocardiography for diagnosing cardiomyopathy. She reported financial relationships with Biomagnetik Park Hoilding, Pfizer, and AstraZeneca.
